Knight Therapeutics Inc. Announces Extension of First Quarter 2020 Filings due to COVID-19
MONTREAL, April 30, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading pan-American (ex USA) specialty pharmaceutical company, announced today that as a result of the COVID-19 impact, Knight will be relying on the temporary relief afforded by DÉCISION N°2020-PDG-0023 of the Autorité des marchés financiers in respect of the obligation to […]
Knight Announces the Re-Launch of Trelstar® in Canada
MONTREAL, April 20, 2020 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has successfully taken over commercial activities from Debiopharm’s previous partner, Allergan. Knight licensed the exclusive rights to commercialize Trelstar® in Canada from Debiopharm, a Swiss-based, global biopharmaceutical company. “We are excited to re-launch […]
Knight Therapeutics Announces Approval of IBSRELA™ in Canada
MONTREAL, April 17, 2020 — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced that Health Canada has approved IBSRELA™ (tenapanor) for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. Knight and Ardelyx, Inc. (NASDAQ: ARDX) signed an agreement in March 2018 granting Knight the exclusive right to distribute […]
Knight Therapeutics Inc. Announces Triumvira Loan Repayment
MONTREAL, April 16, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, announced today that privately-held Triumvira Immunologics Inc. (“Triumvira”) has repaid the outstanding loan balance of US$5 million issued in 2019. In addition, Knight continues to hold rights to commercialize Triumvira’s future approved products in select countries if certain […]
Knight Therapeutics Inc. Announces Completion of its Normal Course Issuer Bid
MONTREAL, April 15, 2020 — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company ”), a leading pan-American (ex-USA) specialty pharmaceutical company, is pleased to announce the completion of its Normal Course Issuer Bid (“NCIB”) launched in July 2019. The Company has purchased a total of 12,053,692 common shares, representing approximately 10% of its public float at […]
Knight Therapeutics Files Annual Information Form
MONTREAL, April 09, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, has filed its Annual Information Form for the year ended December 31, 2019 today. Knight had previously announced that as a result of the COVID-19 impact, it was relying on the temporary relief afforded by DÉCISION N°2020-PDG-0023 […]
Knight Therapeutics Reports Fourth Quarter and Year End 2019 Results
MONTREAL, March 30, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, today reported financial results for its fourth quarter and year ended December 31, 2019. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. 2019 Highlights Financials […]
Notice of Knight Therapeutics’ Fourth Quarter 2019 Results Conference Call and update due to COVID-19 pandemic
MONTREAL, March 27, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter 2019 financial results on Monday, March 30, 2020 after market closing. Following the release, Knight will hold a conference call and audio webcast. Knight cordially invites all interested parties to participate in […]
Knight Announces Closing of Separation Agreement
MONTREAL, March 16, 2020 — Knight Therapeutics Inc. (TSX: GUD) (“Knight“) and Medison Biotech (1995) Ltd. (“Medison“) have closed today the previously disclosed transaction to separate their respective businesses. As announced on November 21, 2019, Knight and Medison have entered into a definitive agreement pursuant to which Knight will sell to the Medison group all […]
Quebec, New Brunswick, Newfoundland, Nova Scotia and Manitoba join Alberta, Saskatchewan, in adding Knight’s PROBUPHINE® to their provincial drug plans in the fight against the opioid crisis
PROBUPHINE® is also listed for reimbursement through the Non-Insured Health Benefit (NIHB) and Veteran Affairs Canada drug plans PROBUPHINE® is the first and only buprenorphine implant approved in Canada for the long-term maintenance management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and […]
